Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2020 17:00 ET | Source: Allogene Therapeutics, Inc.

American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma

ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host DiseaseAbstract Based on Data Cutoff in January...
May 06, 2020 07:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports First Quarter 2020 Financial Results

Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual MeetingPhase 1...
April 29, 2020 11:42 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T TherapyALPHA Study Utilizes ALLO-647 Administered as Part of its Differentiated...
April 28, 2020 16:39 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR™ Technology at the American Society of Gene & Cell Therapy (ASGCT) Virtual 2020 Annual Meeting

Company Developed TurboCAR™ Technology Allows Cytokine Activation Signaling to be Engineered Selectively into CAR T CellsPreclinical Studies Provide Evidence That Cytokine Signaling Can Increase...
April 27, 2020 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
April 01, 2020 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
February 27, 2020 04:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma and Phase 1 ALLO-715 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma On-Track for Q2 2020 and...
February 19, 2020 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
February 06, 2020 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
January 13, 2020 06:00 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

Increasing BCMA Surface Expression with Gamma Secretase Inhibitor Nirogacestat May Enable Deep and Durable Responses to ALLO-715, an Investigational Anti-BCMA Allogeneic CAR T Therapy SOUTH SAN...